{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-23-005621","form_type":"8-K","ticker":"BLCO","cik":"0001860742","company_name":"Bausch & Lomb Corp","filed_at":"2023-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.331122+00:00","generated_at":"2026-06-17T03:16:54.446398+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Bausch + Lomb appoints new Chief Legal Officer and Ophthalmic Pharma President","bullets":["Christina Ackermann steps down as EVP & General Counsel and President, Ophthalmic Pharmaceuticals; departure effective April 28, 2023.","Bob Bailey appointed EVP & Chief Legal Officer, effective April 24, 2023.","Andrew Stewart appointed President, Ophthalmic Pharmaceuticals, effective April 24, 2023.","Bailey previously served as CLO at Datavant and Allergan; Stewart joins from AbbVie eye care.","Both Bailey and Stewart will join the executive management team."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-23-005621","json":"https://secwatch.observer/filing/0000950103-23-005621.json","markdown":"https://secwatch.observer/filing/0000950103-23-005621.md","text":"https://secwatch.observer/filing/0000950103-23-005621.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860742/000095010323005621/0000950103-23-005621-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860742/000095010323005621/dp192149_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T03:16:54.446398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f6dd5c732","claim":"Christina M. Ackermann departed as Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals at Bausch & Lomb Corp.","evidence_excerpt":"On April 12, 2023, Bausch + Lomb Corporation (the “Company”) announced the upcoming departure of Christina M. Ackermann as Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860742/000095010323005621/0000950103-23-005621-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals"}],"fact_type":"executive_change"},{"claim_id":"6fd19eb04a","claim":"Andrew Stewart was appointed as President, Ophthalmic Pharmaceuticals at Bausch & Lomb Corp.","evidence_excerpt":"Andrew Stewart will be appointed as the Company’s President, Ophthalmic Pharmaceuticals","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860742/000095010323005621/0000950103-23-005621-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President, Ophthalmic Pharmaceuticals"}],"fact_type":"executive_change"},{"claim_id":"f2bd81b199","claim":"A. Robert D. Bailey was appointed as Executive Vice President & Chief Legal Officer at Bausch & Lomb Corp.","evidence_excerpt":"A. Robert D. Bailey will be appointed as the Company’s Executive Vice President & Chief Legal Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860742/000095010323005621/0000950103-23-005621-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President & Chief Legal Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}